Abstract
Background: Breast cancer is detected after stage I for many women, particularly women with dense breast tissue and those under 50, due to screening mammography performance and program participation. This report provides data for a new CE-marked blood test currently available in Canada. The test uses a non-fractionated blood sample and involves analysis of a gene expression panel (12 targets) using custom reagents and machine-learning informed software for identification of an active breast cancer signature that has been validated through a retrospective clinical study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
